Epigenetic and RNA-based biomarker validation in Cardiomypathies

Diseases of the heart muscle (cardiomyopathies) are common heart diseases that often have a severe course, up to and including heart failure.

 - Epigenetic and RNA-based biomarker validation in Cardiomypathies

The severity of cardiomyopathy can vary greatly. In addition to the most common form, dilated cardiomyopathy (DCM), there are other forms such as hypertrophic (HCM), arrhythmogenic right ventricular (ARVC), or non-compaction cardiomyopathy (LVNC). The molecular causes of these diseases have not yet been fully clarified. Still, there are strong indications of certain (epi)genetic defects and the influence of environmental factors on the disease. To better understand these diverse causes, the interplay of epigenetic mechanisms on gene regulation and the resulting transcripts (mRNA) is investigated in this project. We use the unique worldwide collection of biomaterials from patients of the "TranslatiOnal Registry for CardiomyopatHies" (TORCH) (PMID: 28772045) to examine several hundred patients and controls. In addition to discovering new molecular irregularities, already known mechanisms and biomarkers are to be checked.I

Publications

There are no publications available yet.

Project Term
11/2021 - 11/2022
Granted Budget
€ 40.000
Research resource used
Resource liquid samples/image data
Keywords
RNA-seq, Cardiomyopathies, biomarker, epigenetics